$Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study$

Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study

Patients with relapsed and refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options after exposure to an immunomodulatory drug, proteasome inhibitor (PI), and anti-CD38 antibody (triple-class exposure [TCE]). However, current understanding about the management of these...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2021-11, Vol.43 (11), p.1983-1996.e3
Hauptverfasser:	Dhanasiri, Sujith, Hollier-Hann, Georgia, Stothard, Catherine, Dhanda, Devender S., Davies, Faith E., Rodriguez-Otero, Paula
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antineoplastic Combined Chemotherapy Protocols Bortezomib CD38 antigen Clinical outcomes Costs Cross-Sectional Studies cross-sectional survey Dexamethasone - therapeutic use End of life Exposure Health care health care resource use Health services Hematology Hospitals Humans Immunomodulating Agents Immunomodulation Medical prognosis Monoclonal antibodies Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Patients Polls & surveys Prognosis Proteasome inhibitors Survival Targeted cancer therapy treatment pattern triple-class exposed United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!